Skip to main
CLOV

CLOV Stock Forecast & Price Target

CLOV Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Clover Health Investments is expected to have continued financial performance and profitability due to their high retention rate, demonstrated results of their software platform in improving health outcomes and lowering costs, and strong growth in markets with high adoption of the platform. Despite potential headwinds in 2027, including being paid as a 3.5-star plan and flat rates for Medicare Advantage plans, the company's focus on technology to improve care and contain costs makes them less dependent on rates for profitability. However, downside risks include regulatory changes, budget deficits, and competition in the Medicare Advantage market. There may also be volatility in medical costs, affecting earnings forecasts and investor confidence.

Bears say

Clover Health Investments is facing a challenging future as they try to maintain profitability while also absorbing new members and sustaining strong cohort economics. There are potential risks such as potential regulatory changes and the need for additional equity financing, which could negatively impact the company's ability to grow and remain profitable. Despite the potential for upside in certain scenarios, overall, the outlook for Clover Health Investments is negative due to these factors.

CLOV has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Clover Health Investments and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Clover Health Investments (CLOV) Forecast

Analysts have given CLOV a Buy based on their latest research and market trends.

According to 3 analysts, CLOV has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.82, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.82, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Clover Health Investments (CLOV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.